Elia Smeir
Overview
Explore the profile of Elia Smeir including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
223
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lohr D, Thiele A, Stahnke M, Braun V, Smeir E, Spranger J, et al.
Front Cardiovasc Med
. 2022 Apr;
9:839714.
PMID: 35449873
Background: Obesity exerts multiple deleterious effects on the heart that may ultimately lead to cardiac failure. This study sought to characterize myocardial microstructure and function in an experimental model of...
2.
Smeir E, Leberer S, Blumrich A, Vogler G, Vasiliades A, Dresen S, et al.
iScience
. 2021 Nov;
24(11):103314.
PMID: 34805785
Cardiolipin (CL) is a major cardiac mitochondrial phospholipid maintaining regular mitochondrial morphology and function in cardiomyocytes. Cardiac CL production includes its biosynthesis and a CL remodeling process. Here we studied...
3.
Smeir E, Kintscher U, Foryst-Ludwig A
Curr Opin Pharmacol
. 2021 Sep;
60:249-254.
PMID: 34482212
Cardiometabolic disorders, such as diabetes, obesity, or metabolic syndrome, are often considered as key comorbidities, leading to the development of different forms of cardiovascular diseases such as heart failure or...
4.
Ritter D, Goeritzer M, Thiele A, Blumrich A, Beyhoff N, Luettges K, et al.
J Am Heart Assoc
. 2021 Jul;
10(14):e019473.
PMID: 34227403
Background It is known that dietary intake of polyunsaturated fatty acids may improve cardiac function. However, relatively high daily doses are required to achieve sufficient cardiac concentrations of beneficial omega-3...
5.
Thiele A, Luettges K, Ritter D, Beyhoff N, Smeir E, Grune J, et al.
Cardiovasc Res
. 2021 Jun;
118(11):2488-2505.
PMID: 34061169
Aims: Heart failure (HF) is characterized by an overactivation of β-adrenergic signalling that directly contributes to impairment of myocardial function. Moreover, β-adrenergic overactivation induces adipose tissue lipolysis, which may further...
6.
Aisen Y, Gatt M, Hertz R, Smeir E, Bar-Tana J
Sci Rep
. 2021 Mar;
11(1):5862.
PMID: 33712631
Treatment of multiple myeloma (MM) aims at inducing cell apoptosis by surpassing the limited capacity of MM cells to cope with oxidative stress. MM cell survival may further be suppressed...
7.
Grune J, Beyhoff N, Smeir E, Chudek R, Blumrich A, Ban Z, et al.
Hypertension
. 2018 Feb;
71(4):599-608.
PMID: 29437893
Mineralocorticoid receptor antagonists (MRAs) reduce morbidity and mortality in chronic heart failure. Novel nonsteroidal MRAs are currently developed and need to be pharmacologically characterized in comparison to classical steroidal MRAs....
8.
Salatzki J, Foryst-Ludwig A, Bentele K, Blumrich A, Smeir E, Ban Z, et al.
PLoS Genet
. 2018 Jan;
14(1):e1007171.
PMID: 29320510
Adipose tissue lipolysis occurs during the development of heart failure as a consequence of chronic adrenergic stimulation. However, the impact of enhanced adipose triacylglycerol hydrolysis mediated by adipose triglyceride lipase...
9.
Alexander-Shani R, Mreisat A, Smeir E, Gerstenblith G, Stern M, Horowitz M
Am J Physiol Regul Integr Comp Physiol
. 2017 Mar;
312(5):R753-R762.
PMID: 28274939
An important adaptive feature of heat acclimation (HA) is the induction of cross tolerance against novel stressors (HACT) Reprogramming of gene expression leading to enhanced innate cytoprotective features by attenuating...
10.
Atiq R, Hertz R, Eldad S, Smeir E, Bar-Tana J
Oncotarget
. 2016 Mar;
7(14):18694-704.
PMID: 26959890
B-Raf(V600E) activates MEK/MAPK signalling and acts as oncogenic driver of a variety of cancers, including melanoma, colorectal and papillary thyroid carcinoma. Specific B-Raf(V600E) kinase inhibitors (e.g., Vemurafenib) prove initial efficacy...